JP2002535658A - 子宮内膜症診断のための方法およびキット - Google Patents
子宮内膜症診断のための方法およびキットInfo
- Publication number
- JP2002535658A JP2002535658A JP2000595159A JP2000595159A JP2002535658A JP 2002535658 A JP2002535658 A JP 2002535658A JP 2000595159 A JP2000595159 A JP 2000595159A JP 2000595159 A JP2000595159 A JP 2000595159A JP 2002535658 A JP2002535658 A JP 2002535658A
- Authority
- JP
- Japan
- Prior art keywords
- endometriosis
- marker
- markers
- endometrial
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 115
- 238000000034 method Methods 0.000 title abstract description 25
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 63
- 239000003550 marker Substances 0.000 claims abstract description 42
- 230000002357 endometrial effect Effects 0.000 claims abstract description 31
- 239000000427 antigen Substances 0.000 claims abstract description 25
- 102000036639 antigens Human genes 0.000 claims abstract description 25
- 108091007433 antigens Proteins 0.000 claims abstract description 25
- 238000002405 diagnostic procedure Methods 0.000 claims description 23
- 238000009007 Diagnostic Kit Methods 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 7
- 239000013610 patient sample Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 18
- 238000003745 diagnosis Methods 0.000 description 16
- 230000035945 sensitivity Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 210000005168 endometrial cell Anatomy 0.000 description 9
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 8
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 238000002357 laparoscopic surgery Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 210000004696 endometrium Anatomy 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 238000002350 laparotomy Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 230000027758 ovulation cycle Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102100029880 Glycodelin Human genes 0.000 description 2
- 101000585553 Homo sapiens Glycodelin Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000009390 immune abnormality Effects 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010065951 Retrograde menstruation Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Devices That Are Associated With Refrigeration Equipment (AREA)
- Measurement Of Mechanical Vibrations Or Ultrasonic Waves (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11703199P | 1999-01-25 | 1999-01-25 | |
| US60/117,031 | 1999-01-25 | ||
| PCT/CA2000/000060 WO2000043789A1 (en) | 1999-01-25 | 2000-01-24 | Method and diagnostic kit for diagnosis of endometriosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002535658A true JP2002535658A (ja) | 2002-10-22 |
| JP2002535658A5 JP2002535658A5 (enExample) | 2007-11-29 |
Family
ID=22370639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000595159A Pending JP2002535658A (ja) | 1999-01-25 | 2000-01-24 | 子宮内膜症診断のための方法およびキット |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1147421B1 (enExample) |
| JP (1) | JP2002535658A (enExample) |
| AT (1) | ATE374370T1 (enExample) |
| AU (1) | AU2088800A (enExample) |
| BR (1) | BR0007702A (enExample) |
| CA (1) | CA2359200A1 (enExample) |
| DE (1) | DE60036536T2 (enExample) |
| ES (1) | ES2292424T3 (enExample) |
| NZ (1) | NZ513692A (enExample) |
| WO (1) | WO2000043789A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024150669A (ja) * | 2019-04-26 | 2024-10-23 | 中外製薬株式会社 | 子宮内膜症の診断方法、病態モニタリング方法及びキット |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003244815A1 (en) * | 2002-02-13 | 2003-09-04 | Metriogene Biosciences Inc. | Cd16b as a marker for the diagnosis of endometriosis |
| US20050100967A1 (en) * | 2003-07-11 | 2005-05-12 | Science & Technology Corporation @ Unm | Detection of endometrial pathology |
| US20060008876A1 (en) | 2004-07-07 | 2006-01-12 | Shami A S E | ME-5, ME-2, and EPP2: human protein antigens reactive with autoantibodies present in the serum of women suffering from endometriosis |
| EP1931993A2 (en) * | 2005-09-14 | 2008-06-18 | Medizinische Universität Wien | Means and methods for diagnosing endometriosis |
| DE102012002929A1 (de) | 2012-02-14 | 2013-08-14 | Jürgen Lewald | Minimalinvasives Verfahren für die Diagnose und die Therapieverlaufskontrolle der Endometriose |
| WO2017039751A1 (en) | 2015-08-28 | 2017-03-09 | Bioincept, Llc | Mutant peptides and methods of treating subjects using the same |
| EP3215847A4 (en) * | 2014-11-03 | 2018-02-14 | Bioincept LLC | Pif binding as a marker for immune dysregulation |
| CA2996874A1 (en) | 2015-08-28 | 2017-03-09 | Bioincept, Llc | Compositions and methods for the treatment of neurodamage |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03202769A (ja) * | 1989-03-07 | 1991-09-04 | Adeza Biomedical Corp | 子宮内膜症診断の方法及び試薬 |
| US5618680A (en) * | 1994-12-28 | 1997-04-08 | Institut De Medecine De La Reproduction De Montreal | Use of ligands specific to major histocompatibility complex-class I antigens for diagnosing endometriosis |
| JP2001501300A (ja) * | 1996-09-06 | 2001-01-30 | オステオメーター・ビオテク・エー／エス | ヒト子宮内膜の生化学的マーカー |
-
2000
- 2000-01-24 BR BR0007702-0A patent/BR0007702A/pt not_active IP Right Cessation
- 2000-01-24 CA CA002359200A patent/CA2359200A1/en not_active Abandoned
- 2000-01-24 AU AU20888/00A patent/AU2088800A/en not_active Abandoned
- 2000-01-24 AT AT00901009T patent/ATE374370T1/de not_active IP Right Cessation
- 2000-01-24 EP EP00901009A patent/EP1147421B1/en not_active Expired - Lifetime
- 2000-01-24 WO PCT/CA2000/000060 patent/WO2000043789A1/en not_active Ceased
- 2000-01-24 NZ NZ513692A patent/NZ513692A/en not_active IP Right Cessation
- 2000-01-24 ES ES00901009T patent/ES2292424T3/es not_active Expired - Lifetime
- 2000-01-24 DE DE60036536T patent/DE60036536T2/de not_active Expired - Lifetime
- 2000-01-24 JP JP2000595159A patent/JP2002535658A/ja active Pending
Non-Patent Citations (2)
| Title |
|---|
| JPN7009004583, Ｗｕ ＭＹ， Ｃｈａｏ ＫＨ， Ｃｈｅｎ ＳＵ， Ｃｈｅｎ ＨＦ， Ｙａｎｇ ＹＳ， Ｈｕａｎｇ ＳＣ， Ｈｏ ＨＮ．, "Ｔｈｅ ｓｕｐｐｒｅｓｓｉｏｎ ｏｆ ｐｅｒｉｔｏｎｅａｌ ｃｅｌｌｕｌａｒ ｉｍｍｕｎｉｔｙ ｉｎ ｗｏｍｅｎ ｗｉｔｈ ｅｎｄｏｍｅｔｒｉｏｓｉｓ ｃｏｕｌｄ ｂｅ ｒｅｓｔｏｒｅｄ ａｆｔｅｒ", Ａｍ Ｊ Ｒｅｐｒｏｄ Ｉｍｍｕｎｏｌ．, 199606, Ｖｏ．３５，Ｎｏ．６, ｐ５１０−５１６ * |
| JPN7009004584, Ｏｔａ Ｈ， Ｉｇａｒａｓｈｉ Ｓ， Ｔａｎａｋａ Ｔ．, "Ｅｘｐｒｅｓｓｉｏｎ ｏｆ ｇａｍｍａ ｄｅｌｔａ Ｔ ｃｅｌｌｓ ａｎｄ ａｄｈｅｓｉｏｎ ｍｏｌｅｃｕｌｅｓ ｉｎ ｅｎｄｏｍｅｔｒｉｏｔｉｃ ｔｉｓｓｕｅ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｅｎ", Ａｍ Ｊ Ｒｅｐｒｏｄ Ｉｍｍｕｎｏｌ．, 199605, Ｖｏｌ．３５，Ｎｏ．５, ｐ４７７−４８２ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024150669A (ja) * | 2019-04-26 | 2024-10-23 | 中外製薬株式会社 | 子宮内膜症の診断方法、病態モニタリング方法及びキット |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE374370T1 (de) | 2007-10-15 |
| BR0007702A (pt) | 2002-09-10 |
| EP1147421A1 (en) | 2001-10-24 |
| WO2000043789A1 (en) | 2000-07-27 |
| EP1147421B1 (en) | 2007-09-26 |
| NZ513692A (en) | 2001-09-28 |
| CA2359200A1 (en) | 2000-07-27 |
| AU2088800A (en) | 2000-08-07 |
| DE60036536D1 (de) | 2007-11-08 |
| ES2292424T3 (es) | 2008-03-16 |
| DE60036536T2 (de) | 2008-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Esteban et al. | Small‐vessel vasculitis surrounding a spared temporal artery: clinical and pathologic findings in a series of twenty‐eight patients | |
| JP5788956B2 (ja) | 食細胞の機能評価方法 | |
| Maeda et al. | Aberrant expression of intercellular adhesion molecule-1 and killer inhibitory receptors induces immune tolerance in women with pelvic endometriosis | |
| Gagné et al. | Development of a nonsurgical diagnostic tool for endometriosis based on the detection of endometrial leukocyte subsets and serum CA-125 levels | |
| ZA200510325B (en) | Monitoring immunologic, hematologic and inflammatory diseases | |
| Anderson et al. | The relative contribution of mast cell subsets to conjunctival TH2-like cytokines | |
| JPH06505332A (ja) | 総白血球表面抗原を用いた治療法及び診断法 | |
| Richter et al. | HLA-DR expression in acute pancreatitis | |
| Murdock et al. | Diagnosis of endometrial biopsies and curettings: a practical approach | |
| Darmochwal-Kolarz et al. | The immunophenotype of patients with recurrent pregnancy loss | |
| US6743595B1 (en) | Method and diagnostic kit for diagnosis of endometriosis | |
| JP2002535658A (ja) | 子宮内膜症診断のための方法およびキット | |
| CA2474890A1 (en) | Method of diagnosis of inflammatory diseases using calgranulin c | |
| US8609432B2 (en) | Method and kit for detection of autoimmune chronic urticaria | |
| WO2020239622A1 (en) | Methods for diagnosing and monitoring sepsis | |
| Robak et al. | Circulating TCR γδ cells in the patients with systemic lupus erythematosus | |
| JP2007532885A (ja) | 急性炎症状態を検出するリアルタイム方法 | |
| Sudo et al. | Antibodies to spermatozoa: IX. Sperm-agglutination phenomenon in cervical mucus in vitro: A possible cause of infertility | |
| US5972594A (en) | Method for screening for reproductive tract inflammation and preeclampsia using neutrophil defensins | |
| US20030219835A1 (en) | CD16b as a marker for the diagnosis of endometriosis | |
| CN113832222A (zh) | 生物标志物在制备用于诊断流产的试剂盒中的用途 | |
| RU2077727C1 (ru) | Способ диагностики угрозы невынашивания плода в первом триместре беременности | |
| Stabile et al. | Spontaneous abortion: diagnosis and treatment | |
| CA2153975C (en) | Marker for crohn's disease and multiple sclerosis | |
| US20080131914A1 (en) | Assessing risk of cerebrovascular thrombosis by measuring c4d |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071011 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20091001 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091016 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100115 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100122 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100216 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100223 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100316 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100324 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100629 |